Date: 2017-03-06
Type of information: Research agreement
Compound:
Company: Servier (France) Vernalis (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D - research
Action mechanism:
Disease:
Details:
- • On March 6, 2017, Vernalis and Servier announced that they reinforce their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target.
This agreement extends the existing successful collaborations between Servier and Vernalis since 2007, to combine Vernalis’ proprietary fragment- and structure-based drug discovery platform with the oncology expertise at Servier. Previous successes include discovery of products targeting Bcl-2 and Mcl-1 currently in clinical development.
Financial terms:
- Vernalis will receive a €2 million upfront payment, fees, research milestones and a share in the downstream success of any products coming out of this new collaboration.
Latest news:
Is general: Yes
